Login to Your Account

No SPA for Cabo Phase III in CRPC; Exelixis Plummets

By Tom Wall
BioWorld Today Contributing Writer

Wednesday, November 2, 2011

Exelixis Inc.'s stock plummeted 40.2 percent Tuesday following the South San Francisco biotech's announcement that it was unable to secure a special protocol assessment (SPA) from the FDA for its pivotal Phase III XL184-306 trial of cabozantinib (cabo) in end-stage castrate resistant prostate cancer (CRPC).

Exelixis said it has stopped pursuing the SPA and plans to initiate the '306 trial by the end of 2011 with pain as the primary efficacy endpoint, to be followed in the first half of 2012 by the Phase III XL184-307 trial to evaluate overall survival time.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription